Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- efbemalenograstim alfa
- Ibrance (palbociclib)
Interactions between your drugs
palbociclib efbemalenograstim alfa
Applies to: Ibrance (palbociclib), efbemalenograstim alfa
Using efbemalenograstim alfa before, during, or too soon after completion of a course of palbociclib may alter the effects of either medication. Efbemalenograstim alfa should generally not be given from 14 days before until 24 hours after cancer chemotherapy. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
palbociclib food
Applies to: Ibrance (palbociclib)
Palbociclib oral capsules (Ibrance) should be taken with food to help with its absorption. Palbociclib oral tablets (Ibrance) may be taken with or without food. Do not consume grapefruit or grapefruit juice during treatment with palbociclib. Grapefruit and grapefruit juice can interact with palbociclib and increase the levels of palbociclib in your body. You may be more likely to experience side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; hair loss; weakness; pain, numbness, or tingling in the hands and feet; and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Zarxio
Zarxio (filgrastim-sndz) is biosimilar product used to treat neutropenia associated with ...
Neulasta
Neulasta is used to stimulate neutrophil growth and reduce infection risk (manifested by febrile ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Neupogen
Neupogen (filgrastim) is used to treat neutropenia, a lack of certain white blood cells caused by ...
Nivestym
Nivestym is used for bone marrow transplantation, neutropenia, neutropenia associated with ...
Fulphila
Fulphila is used for febrile neutropenia, neutropenia associated with chemotherapy
Udenyca
Udenyca is used for febrile neutropenia, hematopoietic syndrome of acute radiation syndrome ...
Releuko
Releuko is used for bone marrow transplantation, neutropenia, neutropenia associated with chemotherapy
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.